Natco Pharma announces launch of Carboplatin Injection (generic of Paraplatin) in the U.S. market

19th October, 2026 Corporate Relationship Department Manager – Listing BSE Ltd. National Stock Exchange of India Ltd Mumbai 400 001 Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the above cited subject, please find enclosed herewith the Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This is for your information. Thanking you, Yours faithfully For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer Natco Pharma Limited Regd. Off. Press Release NATCO Pharma Ltd Natco House Road No.2, Banjara Hills Hyderabad-500 034, India NATCO announces launch of Carboplatin Injection (generic of Paraplatin®) in the U.S. market Hyderabad, India, October 19th, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announces launch of Carboplatin Injection, a generic version of Paraplatin® in the U.S. market by its U.S. subsidiary NATCO Pharma USA LLC. NATCO launches this product in manufacturing collaboration with Teyro Labs Pvt Ltd, based in Chennai. This launch helps address a critical shortage of the product in the U.S. market. Carboplatin Injection is indicated for the treatment of advanced ovarian carcinoma, including first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy. Please refer to the full Prescribing Information for complete indications, limitations, and important safety information. Carboplatin Injection had estimated sales of USD 27.8 million in the U.S. for 12 months ending June’26 as per industry sales data. *Safe Harbor Statement All brand names and trademarks are the property of their respective owners About NATCO Pharma Limited NATCO Pharma Limited, (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies in domestic market and focuses on limited competition molecules in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company’s manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com. For further information or queries on the press release please contact: Rajeev Menon – Investor Relations Email: r.menon@natcopharma.co.in Tel: 040-23547532 / Ext – 323